N-Acetylcarnosine

Drug Profile

N-Acetylcarnosine

Alternative Names: Can-C; NAC - Innovative Vision Products; Nu-Eyes

Latest Information Update: 18 Jul 2007

Price : $50

At a glance

  • Originator Innovative Vision Products
  • Class Dipeptides; Eye disorder therapies; Neuropeptides
  • Mechanism of Action Antioxidants; Glycosylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Cataracts
  • Phase Unknown Eye disorders

Most Recent Events

  • 18 Jul 2006 Launched for Cataracts in World (Ophthalmic)
  • 18 Jul 2004 Investigation in Eye disorders in USA (Ophthalmic)
  • 16 Apr 2002 Clinical trials in Cataracts in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top